Latest PolyMedix Inc. Stories
As the first step in PolyMedixâ€™s US clinical development activities with PMX-30063, it has initiated a Phase 1 clinical trial. (Vocus/PRWEB) January 12, 2011 Last November, PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, received regulatory clearance from the FDA to investigate its new antibiotic candidate, PMX-30063.
RADNOR, Pa., April 5 /PRNewswire-FirstCall/ -- Polymedix Inc announces the following Webcast: What: PMX-30063 Phase 1B Clinical Study Results When: April 6, 2010 @ 10:00 AM Eastern Where: http://www.investorcalendar.com/ClientPage.asp?ID=156938 Live
SAN FRANCISCO, Nov. 17 /PRNewswire-FirstCall/ -- Merriman Curhan Ford Group, Inc. (Nasdaq: MERR) acted as lead placement agent in PolyMedix Inc.'s (OTC Bulletin Board: PYMX) $20.7 million registered public offering of 20.7 million units.
KING OF PRUSSIA, Pa., Dec. 11 /PRNewswire/ -- Emerging Growth Equities, Ltd. initiates coverage of PolyMedix Inc. (OTC Bulletin Board: PYMX) with a BUY rating and a $9.00 price target.
PolyMedix Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced today that it has completed a $4.25 million private placement of preferred stock units.
PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a Phase I clinical study in the U.S.
- Forsooth! indeed! originally a parenthetical phrase used in repeating the words of another with more or less contempt or disdain.